Clinical trials: Lipid Disorders
Hypercholesterolemia
Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)
The overall objective is to evaluate the efficacy and safety of ezetimibe (SCH 058235/MK-0653) 10 mg administered daily in conjunction with atorvastatin in participants with Heterozygous Familial Hypercholesterolemia (HeFH) or in…
- Trial name
- NCT03867318
- Testing
- Atorvastatin, Ezetimibe
- Volunteers
- 621 people
- Sponsor
- Organon and Co
Lipedema, Dercum Disease
Treatment of Women With Lipedema Involving Substantial Fat Knee of Women and Men With Nodular Dercum's Disease
This is an open label, 2 cohort, clinical trial in women with lipedema with substantial fat above the knee and men with Dercum's disease. Each cohort will have 6 subjects who will receive RZL-012.
- Trial name
- NCT03492840
- Testing
- RZL-012
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Raziel Therapeutics Ltd.
Hypercholesterolemia
(H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol
The primary objective of the study is to demonstrate that the performance of the modified Plasmat® Futura H.E.L.P. Apheresis System is non-inferior to the current FDA approved Plasmat® Secura H.E.L.P Apheresis System for use…
- Trial name
- FUTURA (NCT00526058)
- Testing
- Secura then Futura, Futura then Secura
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- B. Braun Medical Inc.
Hypercholesterolemia
Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)
Participants currently taking atorvastatin 20 mg will be switched to either atorvastatin 40 mg or ezetimibe/simvastatin 10 mg/40 mg (10/40).
- Trial name
- NCT00782184
- Testing
- ezetimibe/simvastatin 10/40, atorvastatin 40 mg, atorvastatin 20 mg
- Volunteers
- 250 people
- Sponsor
- Organon and Co
Type I Gaucher Disease
Clinical Trial of Ambroxol in Patients With Type I Gaucher Disease
Ambroxol is expected to improve the signs and symptoms of patients with Type I Gaucher Disease.
- Trial name
- NCT01463215
- Testing
- Ambroxol
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Exsar Corporation
Hypercholesterolemia
Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin
To evaluate the Low Density Lipoprotein-Cholesterol (LDL-C) lowering effect of PF-04950615 administered subcutaneously at monthly intervals, or twice monthly intervals in subjects with high cholesterol whose LDL-cholesterol is…
- Trial name
- NCT01592240
- Testing
- PBO, 200mg PF-04950615 (RN316), 300mg PF-04950615 (RN316)
- Where
- 74 sites in United States
- Volunteers
- 354 people
- Sponsor
- Pfizer
Fabry Disease
A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms
The purpose of this study was to determine whether 2 alternative dosing regimens of Fabrazyme (Agalsidase beta) (1.0 mg/kg every 4 weeks or 0.5 mg/kg every 2 weeks) were effective in treatment-naïve pediatric participants without…
- Trial name
- FIELD (NCT00701415)
- Testing
- Agalsidase beta
- Where
- 12 sites in United States, Argentina and 7 more
- Volunteers
- 31 people
- Sponsor
- Genzyme, a Sanofi Company
Hypertension, Dyslipidemias
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(6)
A phase I clinical trial to evaluate the tolerability and the pharmacokinetics of CKD-348(6).
- Trial name
- NCT06112678
- Testing
- CKD-348(6), CKD-828, D097, D337
- Where
- South Korea
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Late-infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)
A Retrospective, Natural History Study in Children With CLN2
This is a multi center, retrospective, chart review study to document the evolution of ocular disease progression in pediatric patients with CLN2.
- Trial name
- NCT04480476
- Sponsor
- REGENXBIO Inc.
HIV Infections
Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial
Primary objective: Evaluation of the efficacy of TDF+3TC+EFV versus TDF+EFV QD to maintain plasma HIV-1 RNA BLQ (< 50 copies/mL) (c/mL) at 48 weeks (W48) Main Secondary objectives: Comparison of the two arms for genotypic…
- Trial name
- COOL (NCT00643968)
- Testing
- EFV+TDF, EFV+3TC+TDF
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Gilead Sciences
Hypertension, Dyslipidemia
Caduet in an Untreated Subject Population
The purpose of this study is to determine if Caduet will lower blood pressure to <140/90 mmHg and lower LDL Cholesterol to <100 mg/dL in subjects with hypertension and dyslipidemia who are not currently being treated for these…
- Trial name
- CUSP (NCT00332761)
- Testing
- Caduet
- Where
- 34 sites in United States
- Volunteers
- 220 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypercholesterolemia
Efficacy and Safety of HEP-40 Chitosan for Mild to Moderately Elevated Cholesterol
Chitosan is a natural product that is produced commercially through the deacetylation of chitin, which is found in the exoskeleton of crustaceans. It has been suggested that chitosan has a lipid-lowering effect.
- Trial name
- HEP-40 (NCT00454831)
- Testing
- HEP-40 chitosan
- Where
- Canada
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- DNP Canada
Atopic Dermatitis
Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis
Atopic dermatitis (AD) is a common skin disease that has increased in prevalence worldwide two- to threefold over the last 50 years.
- Trial name
- NCT00460083
- Testing
- Elidel(R) (pimecrolimus 1%), EpiCeram(R) -ceramide based barrier repair cream
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Ceragenix Pharmaceuticals
Dercum's Disease
A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas
This is a single-blind, placebo-controlled, randomized phase 2 study to evaluate the efficacy and safety of CBL-514 injections in participants with Dercum's Disease lipomas.
- Trial name
- NCT06303570
- Testing
- CBL-514 injection, 0.9% Sodium chloride
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
Dyslipidemia
Cholesterol Goal Attainment Rate and Its Associated Factors Among Dyslipidemic Patients on Lipid-lowering Drug Therapy in Korea
This is a multi-centre, cross-sectional, chart review study to investigate cholesterol goal attainment rates defined by modified NCEP-ATP III guidelines and define its possible determinants among Korean dyslipidemic patients
- Trial name
- CRESENDO (NCT01372956)
- Where
- 20 sites in South Korea
- Volunteers
- 4,950 people
- Sponsor
- AstraZeneca
Neuronal Ceroid Lipofuscinosis Type 2
A Registrational Study of TTX-381 to Treat Vision Loss in CLN2 Disease
This is a registrational, first-in-human, open-label, dose escalation and expansion study evaluating the safety, tolerability and effectiveness of TTX-381, administered by injection under the retina, for the treatment of eye…
- Trial name
- NCT05791864
- Testing
- TTX-381
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 26 people
- Sponsor
- Tern Therapeutics, LLC
Familial Hypercholesterolemia - Homozygous
Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia
This was a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in adolescents with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein cholesterol (LDL-C).
- Trial name
- ORION-13 (NCT04659863)
- Testing
- Inclisiran
- Where
- 11 sites in United States, Canada and 6 more
- Volunteers
- 13 people
- Sponsor
- Novartis Pharmaceuticals
Hyperlipemia
Safety and Tolerability of SHR-1918 in Healthy Subjects
The primary objective of this study is to assess the safety and tolerability of SHR-1918 injection in healthy subjects. In addition, this study will provide information on pharmacokinetics and pharmacodynamics of SHR-1918…
- Trial name
- NCT05432544
- Testing
- SHR-1918
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Diabetes Mellitus
Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to determine the efficacy and safety of SYR-472, once daily (QD), in subjects with type 2 diabetes mellitus who have not achieved glycemic control with diet and exercise, or by taking metformin.
- Trial name
- NCT00760344
- Testing
- SYR-472, Sitagliptin
- Where
- 112 sites in United States, Mexico
- Volunteers
- 386 people
- Sponsor
- Takeda
Primary Hyperlipidemia
A Clinical Study to Evaluate the Efficacy, Tolerability, and Safety of Bempedoic Acid
This trial is a phase III study to evaluate the efficacy , tolerability, and safety of Bempedoic Acid Tablets in patients with hyperlipidemia not adequately controlled by Statins.
- Trial name
- NCT06780410
- Testing
- Bempedoic Acid Tablet
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Gan & Lee Pharmaceuticals.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.